Evidence map›Paper›PMID 42536733›Full record

ArticleScience advances2026

Engineered heart-liver axis nanoregulators synergize autophagy activation and systemic metabolic reprogramming against atherosclerosis.

Yiyong Tang, Jiadi Liu, Liya Tian, Bowen Shen, Tairen Zhou, Shen Zhao, Qianqian Gao, Mingda Du, Yuanchen Sun, Xiao Sun and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yiyong TangCardiovascular Ultrasound Department, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.ORCID 0009-0006-0540-2035
Jiadi LiuShandong Cancer Hospital and Institute, School of Chemistry and Pharmaceutical Engineering, Medical Science and Technology Innovation Center, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Liya TianShandong Cancer Hospital and Institute, School of Chemistry and Pharmaceutical Engineering, Medical Science and Technology Innovation Center, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Bowen ShenShandong Cancer Hospital and Institute, School of Chemistry and Pharmaceutical Engineering, Medical Science and Technology Innovation Center, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Tairen ZhouSchool of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, China.
Shen ZhaoShandong Cancer Hospital and Institute, School of Chemistry and Pharmaceutical Engineering, Medical Science and Technology Innovation Center, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Qianqian GaoShandong Cancer Hospital and Institute, School of Chemistry and Pharmaceutical Engineering, Medical Science and Technology Innovation Center, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Mingda DuShandong Cancer Hospital and Institute, School of Chemistry and Pharmaceutical Engineering, Medical Science and Technology Innovation Center, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Yuanchen SunCardiovascular Ultrasound Department, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Xiao SunShandong Cancer Hospital and Institute, School of Chemistry and Pharmaceutical Engineering, Medical Science and Technology Innovation Center, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.ORCID 0000-0001-6506-1574
Houren ZhouCardiovascular Ultrasound Department, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.ORCID 0000-0003-4616-1849
Weihai XuDepartment of Neurology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID 0000-0003-3874-2598
Jun WuCardiovascular Ultrasound Department, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.ORCID 0000-0002-6807-8619

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atherosclerosis (AS) is the most important pathological basis for cardiovascular diseases worldwide. However, the current mainstream therapeutic strategies for AS only target isolated pathological links, ignoring hepatic steatosis as a related risk factor for AS, which leads to limited effectiveness in controlling the overall course of atherosclerosis. Herein, a smart nanoplatform that can synergistically regulate AS and hepatic steatosis was first reported, which featured sulfide iron nanosheets as the core, grafted with bovine myeloid antimicrobial peptide 27 (BMAP-27), skillfully coated with an erythrocyte-macrophage hybrid biomimetic membrane. First, this nanoplatform is capable of targeting atherosclerotic plaques. When combined with low-intensity focused ultrasound, the nanoplatform markedly enhanced local drug accumulation. The localized temperature rise generated by near-infrared laser irradiation acted to open TRPV1 channels, facilitating Ca

Indexed as

AtherosclerosisAutophagyLiverMyocardiumAnimalsCalciumCattleHumansMetabolic ReprogrammingMiceReactive Oxygen SpeciesCalciumReactive Oxygen Species

Identifiers

PMID42536733
PMCPMC13426405

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.